Delving into the Latest Updates on Liraglutide biosimilar(Zhuhai United Laboratories) with Synapse

Overview

Basic Info

Drug Type

Recombinant polypeptide, Biosimilar

Synonyms-

Target

GLP-1R

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Zhuhai United Laboratories Holding Ltd.

Active Organization

Zhuhai Federal Biomedical Co., Ltd.

Zhuhai United Laboratories Holding Ltd.

Inactive Organization-

Drug Highest PhaseNDA/BLA

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 50953

The sequence is quoted from: *****

To investigate the pharmacokinetic characteristics of liraglutide injection, and compare the pharmacokinetic similarity and safety of a single subcutaneous injection of liraglutide injection (test preparation) with that of the original product (reference preparation) in healthy Chinese adult subjects.

Start Date29 May 2019

Sponsor / Collaborator

Zhuhai United Laboratories Holding Ltd.

100 Clinical Results associated with Liraglutide biosimilar(Zhuhai United Laboratories)

Login to view more data

100 Translational Medicine associated with Liraglutide biosimilar(Zhuhai United Laboratories)

Login to view more data

100 Patents (Medical) associated with Liraglutide biosimilar(Zhuhai United Laboratories)

Login to view more data

100 Deals associated with Liraglutide biosimilar(Zhuhai United Laboratories)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	NDA/BLA	CN	Zhuhai Federal Biomedical Co., Ltd.	22 Aug 2023
Diabetes Mellitus, Type 2	NDA/BLA	CN	Zhuhai United Laboratories Holding Ltd.	22 Aug 2023